Votrient is a new medication used for the treatment of renal cell carcinoma. It belongs to a group of drugs called multi-tyrosine kinase inhibitor. Multi-tyrosine kinases are molecules that are responsible for the growth, progression and metastasis of renal cell carcinoma. Treatment of renal cell carcinoma with votrient stops the actions of these molecules and help to decrease the progression of the disease. Only advanced renal cell carcinoma is treated with votrient. It is made and marketed by GlaxoSmithKline.
How is votrient administered for the treatment of renal cell carcinoma?
Votrient comes in tablet form. The most common starting dose is 800 mg, once a day. It is taken in empty stomach, one to two hours before eating.
How effective is votrient treatment in renal cell carcinoma?
The effect of votrient for renal cell carcinoma is determined by progression-free survival. In simple terms, progression-free survival is the length of time during and after the treatment the disease does not get worse. Treatment of renal cell carcinoma with votrient gives a progression-free survival of approximately 9.2 months. This means votrient treatment can stop the worsening of renal cell carcinoma for approximately 9.2 months. However, it does not prolong the lifespan of patients.
What are the adverse side effects of votrient treatment in renal cell carcinoma patients?
Renal cell carcinoma patients who are treated with votrient experience many adverse side effects. This does not mean that all patients who take the medication will experience all of these side effects. These are patient-specific. The general adverse side effects of votrient treatment include high blood pressure, liver complications, diarrhea, nausea, anorexia, abnormal heart function, abnormal liver enzymes, stroke and gastrointestinal problems and many more.
How is votrient administered for the treatment of renal cell carcinoma?
Votrient comes in tablet form. The most common starting dose is 800 mg, once a day. It is taken in empty stomach, one to two hours before eating.
How effective is votrient treatment in renal cell carcinoma?
The effect of votrient for renal cell carcinoma is determined by progression-free survival. In simple terms, progression-free survival is the length of time during and after the treatment the disease does not get worse. Treatment of renal cell carcinoma with votrient gives a progression-free survival of approximately 9.2 months. This means votrient treatment can stop the worsening of renal cell carcinoma for approximately 9.2 months. However, it does not prolong the lifespan of patients.
What are the adverse side effects of votrient treatment in renal cell carcinoma patients?
Renal cell carcinoma patients who are treated with votrient experience many adverse side effects. This does not mean that all patients who take the medication will experience all of these side effects. These are patient-specific. The general adverse side effects of votrient treatment include high blood pressure, liver complications, diarrhea, nausea, anorexia, abnormal heart function, abnormal liver enzymes, stroke and gastrointestinal problems and many more.
No comments:
Post a Comment